Seattle Genetics Reports Data From Collaborator ADC Programs - Quick Facts

(RTTNews) - Seattle Genetics Inc. (SGEN) announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Seattle Genetics and its collaborators, including Genentech, AbbVie and Progenics, have nine data presentations at ASCO. All of the collaborator programs utilize Seattle Genetics' ADC technology.

AbbVie presented preliminary data from an ongoing phase 1 clinical trial evaluating the ADC ABT-414 in combination with temozolomide in glioblastoma. The data demonstrated antitumor activity in the treatment of glioblastoma. The phase 1 study is ongoing and phase 2 studies are being planned.

Genentech, a member of the Roche Group, presented data from five ADC programs, including two oral presentations.

Progenics presented data from an ADC program under evaluation for castration-resistant prostate cancer.